30.91USD+5.35%Mkt Cap: 1.92B USDP/E: —Last update: 2026-05-26
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap1.92B USD
Enterprise Value1.51B USD
Revenue (TTM)32.08M USD
Gross Profit32.08M USD
Net Income (TTM)-6.88M USD
Revenue/Share0.5300 USD
Last Price30.91 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees170
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS86150R1077
Valuation
P/E (Trailing)—
P/E (Forward)-9.56
PEG—
EV/EBITDA-8.22
EV/Revenue47.00
P/S57.60
P/B4.96
EPS (TTM)-2.86
EPS (Forward)-3.10
52W Range
9.09070% of range40.22
52W High40.22 USD
52W Low9.090 USD
Profitability
Gross Margin100.00%
Oper. Margin-857.57%
EBITDA Margin0.00%
Profit Margin-3.73%
ROE-1.95%
ROA-1.65%
Growth
Revenue Growth-96.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF45.59M USD
CapEx (TTM)670.00K USD
FCF Margin-276.45%
FCF Yield-4.62%
Net Debt-340.12M USD
Net Debt/EBITDA1.85
Balance Sheet
Debt/Equity0.01
Current Ratio8.99
Quick Ratio8.57
Book Value/Sh5.982 USD
Cash/Share5.516 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)45.10 USD
Target Range35.00 USD – 60.00 USD
# Analysts10
Ownership
Shares Out.62.28M
Float46.76M
Insiders3.82%
Institutions120.33%
Short Interest
Short Ratio23.1d
Short % Float21.76%
Short % Out.20.92%
Shares Short13.03M
Short (prev mo.)12.82M
Technical
SMA 5033.29 (-7.2%)
SMA 20029.54 (+4.6%)
Beta1.20
S&P 52W Chg28.31%
Avg Vol (30d)530.63K
Avg Vol (10d)638.62K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—